BryantL.M., ChristopherD.M., GilesA.R.et al.2013. Lessons learned from the clinical development and market authorization of Glybera. Hum. Gene Ther. Clin. Dev., 24:55–64.
GruppS.A., KalosM., BarrettD.et al.2013. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med., 368:1509–1518.
4.
Hacein-Bey-AbinaS., GarrigueA., WangG.P.et al.2008. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest., 118:3132–3142.
5.
MaguireA.M., SimonelliF., PierceE.A.et al.2008. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med., 358:2240–2248.
6.
NathwaniA.C., TuddenhamE.G., RangarajanS.et al.2011. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med., 365:2357–2365.
7.
RaperS.E., ChirmuleN., LeeF.S.et al.2003. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab., 80:148–158.
8.
SeguraM.M., MangionM., GailletB., GarnierA.2013. New developments in lentiviral vector design, production and purification. Expert Opin. Biol. Ther., 13:987–1011.
9.
ShillerR.J.2005. Irrational Exuberance, 2nd. Princeton University Press: Princeton, NJ.
10.
WilsonJ.M.2009. Medicine: A history lesson for stem cells. Science, 324:727–728.
